drugset

drugset / Trial / NCT00566241

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241 ↗

Phase 1 Terminated 15 enrolled Stony Brook University

RandomizedCrossoverQuadruple-blindTreatment

Summary

28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.

Timeline

Start: 2008-06
Primary completion: 2012-06
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mecasermin	Protein / enzyme biologic	—	—

Indications